Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Endologix Inc (ELGX) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 607,780
  • Shares Outstanding, K 82,370
  • Annual Sales, $ 153,610 K
  • Annual Income, $ -50,420 K
  • 36-Month Beta 0.97
  • Price/Sales 3.72
  • Price/Book 4.27

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.22 +13.34%
on 11/16/16
10.36 -31.95%
on 11/14/16
-2.10 (-22.95%)
since 11/02/16
3-Month
6.22 +13.34%
on 11/16/16
13.30 -46.99%
on 09/22/16
-5.17 (-42.31%)
since 09/02/16
52-Week
6.22 +13.34%
on 11/16/16
14.49 -51.35%
on 07/12/16
-3.23 (-31.42%)
since 12/02/15

Most Recent Stories

More News
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Endologix Inc. - ELGX

Levi & Korsinsky announces it has commenced an investigation of Endologix Inc. (NASDAQ:ELGX) ("Endologix") concerning possible violations of federal securities laws by the Company and/or...

Endologix Provides Update on Nellix PMA Process

Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the U.S Food and Drug Administration (FDA) has requested the Company provide 2-year...

Endologix to Participate in Four Investor Conferences in November 2016

Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer,...

Endologix Down 23.9% Since SmarTrend Downtrend Call (ELGX)

SmarTrend identified a Downtrend for Endologix (NASDAQ:ELGX) on August 12th, 2016 at $11.73. In approximately 3 months, Endologix has returned 23.91% as of today's recent price of $8.93.

Endologix Reports Results for the Third Quarter 2016

Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2016.

Endologix Appoints Matthew Thompson, M.D., as Chief Medical Officer

Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced the appointment of Matthew Thompson, M.D., as Chief Medical Officer effective December 2016....

Endologix Announces Release Date for Third Quarter 2016 Financial Results and Details of 2016 Investor Meeting

Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its third quarter 2016 financial results, which will...

Medical Product Stocks' Oct 24 Earnings Preview: ELGX, VASC

There is some definite good news for investors keen on the Medical sector.

How These Healthcare Stocks are Faring? -- Endologix, TransEnterix, Becton, Dickinson, and OraSure Technologies

This morning Stock-Callers.com has initiated research reports on these four healthcare stocks: Endologix Inc. (NASDAQ: ELGX), TransEnterix Inc. (NYSE MKT: TRXC), Becton, Dickinson and Company (NYSE: BDX),...

Endologix Reports Positive Clinical Data from Ovation(R) LIFE (Least Invasive Fast-Track EVAR) Study

Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today positive clinical data from the Ovation LIFE (Least Invasive Fast-Track EVAR) study....

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment...

See More

Support & Resistance

2nd Resistance Point 7.28
1st Resistance Point 7.17
Last Price 7.05
1st Support Level 6.87
2nd Support Level 6.68

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.